About the Journal. Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; immunotherapy; gene therapy; diagnostic biomarkers; innovative …

Cancer Discovery ; Cancer Epidemiology, Biomarkers & Prevention ; Cancer Immunology Research ; Cancer Prevention Research ; Cancer Research ; Cancer Research Communications ; Clinical Cancer Research ; Molecular Cancer Research ; Molecular Cancer Therapeutics ; For Authors . Information for Authors ; Author Services ; Journal Awards ; About Us ...

About Clinical Cancer Research Scope. Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to …

Clinical Cancer Research is interested in reports of clinical trials that involve both early and late stages of drug development. Clinical trial manuscripts should include a clear statement of the primary objective of the study, patient eligibility criteria, the measured endpoints, and the statistical approach and analysis (particularly for any biomarker hypotheses).

2025年1月15日 · Clinical Cancer Research | 31 | 2 | January 2025. NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific …

2023年10月15日 · Clinical Cancer Research | 29 | 20 | October 2023. NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any …

6 天之前 · Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2 + , triple negative and metastatic ER + /HER2 - breast cancers

Clinical Cancer Research (CCR) publishes innovative clinical trials and translational cancer research studies that bridge the laboratory and the clinic.The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment.

Omar Abdel-Wahab Hematological cancers, genome biology, gene regulation, molecular oncology. Susan G. Hilsenbeck Applied biostatistics, biostatistical and informatics collaboration, design and statistical analysis of translational experiments and clinical trials, design and analysis of prognostic and predictive biomarker studies, identification and validation of prognostic and …

2024年1月1日 · Clinical Cancer Research | 30 | 1 | January 2024. NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific …